Sign inJoin waitlistJoin the waitlist

Daniel L. Mulkerin

Professor - Department of Medicine, Hematology/Oncology · URochester Medicine

Credentials: · · · ·

History

URochester Medicine
Present
URochester Medicine
Present

University of Wisconsin Hospital and Clinics
1996–1999
University of Wisconsin Hospital and Clinics
1993–1996
University of Wisconsin Hospital and Clinics
1992–1993
Thomas Jefferson University Hospital
1992

Research

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized…
JAMA · 2017 · 770 citations
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Journal of Clinical Oncology · 2003 · 79 citations
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute…
Journal of Clinical Oncology · 2008 · 77 citations

Noelle LoConte
18 papers · 1 as a resident
Sam Lubner
16 papers · 1 as a resident
KH
Kyle Holen
12 papers
Dustin Deming
10 papers · 1 as a fellow
CT
Christopher Takimoto
9 papers
RR
Ramesh Ramanathan
9 papers
Scot Remick
8 papers
Sridhar Mani
8 papers
HR
H Robins
7 papers
Heinz-Josef Lenz
7 papers
WS
William Schelman
7 papers
GW
George Wilding
6 papers

Clinical trials

Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
Vaccinex Inc.
2022–2028
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Principal investigator · Active not recruiting · Phase 1
University of Rochester
2020–2026
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 2
University of Wisconsin, Madison
2004–2007
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2003